The Biden administration has introduced a proposed rule to expand Medicare and Medicaid coverage for FDA-approved anti-obesity medications (AOMs) in the United States, recognizing obesity as a chronic disease requiring comprehensive treatment.
If finalized, the expanded coverage would take effect in 2026. Key coverage changes would include the following:
Medicare Part D Expansion
- Coverage for AOMs prescribed specifically to treat obesity, even in the absence of other medical conditions.
- Eligibility would apply to beneficiaries with a body mass index (BMI) of 30 or higher.
Medicaid Coverage Standardization
- State Medicaid programs would be required to cover AOMs unless they opt out.
- The coverage would reduce disparities in access to obesity treatments among low-income populations.
FDA-Approved Medications Only
- Coverage would be limited to AOMs approved by the U.S. Food and Drug Administration (FDA).
- It would exclude compounded drugs, over-the-counter supplements, or treatments not approved for obesity.